Application of combination of ACTR10 and CA125 in ovarian cancer detection and kit

A CA125, detection reagent technology, applied in the field of medical diagnosis, can solve problems such as insufficient diagnostic sensitivity and specificity

Active Publication Date: 2022-04-22
上海晟燃生物科技有限公司
View PDF9 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, the diagnostic sensitivity and specificity of such technical solutions are not ideal and still need to be improved.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of ACTR10 and CA125 in ovarian cancer detection and kit
  • Application of combination of ACTR10 and CA125 in ovarian cancer detection and kit
  • Application of combination of ACTR10 and CA125 in ovarian cancer detection and kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] Differential detection of ACTR10 expression in stage I ovarian cancer patients and non-ovarian cancer individuals

[0076] Different detection methods of ACTR10 can detect the difference in the expression of stage I ovarian cancer patients and non-ovarian cancer individuals.

[0077] The concentration of ACTR10 was detected by chemiluminescent method, and the results are shown in figure 1 : The average value of patients with stage I ovarian cancer is 16.2U / ml (that is, 16.2U ACTR10 protein per ml of plasma), and the average value of patients with benign ovarian diseases is 33.3 U / ml. The p value of the two groups of statistical tests is less than 0.0001. The average value of healthy individuals is 39.01 U / ml, and the p-value of the statistical test between the stage I ovarian cancer patient group and the healthy individual group is less than 0.0001.

[0078] The concentration of ACTR10 was detected by flow fluorescence method, and the results are shown in figure 2 : ...

Embodiment 2

[0081] Expression detection of ACTR10 in different cancer patients

[0082] ACTR10 is specifically expressed in plasma vesicles of ovarian cancer patients. In the prior art solutions, the method for detecting several miRNAs in vesicles will affect the specificity of ovarian cancer diagnosis. The expression of the same miRNA is increased in a variety of tumors.

[0083] In this example, ACTR10 in different cancer patients was detected by chemiluminescence, and the results are shown in image 3 : ACTR10 was not significantly different in plasma vesicles of patients with other common tumors or benign diseases in women; in breast cancer, breast benign cystic hyperplasia, cervical cancer, cervical benign leiomyoma and corresponding healthy individuals, the There was no significant difference in concentration, and the average values ​​of each group were: 32.65, 32.32, 33.37, 30.94, 35.73 U / ml.

Embodiment 3

[0085] The combination of ACTR10 and CA125 is used for auxiliary diagnosis of early ovarian cancer.

[0086] A total of 100 gynecological outpatients were enrolled. The inclusion criteria were CA125 in the range of 35U to 100U / ml, abdominal discomfort, and vaginal ultrasound showing ovarian space-occupying lesions, but laparoscopy had not yet been performed. Use the chemiluminescence platform to detect ACTR10 in the plasma vesicles of the above 100 women and substitute the value of CA125 into the auxiliary diagnosis model of ovarian cancer: OCS1=0.38×C CA125 -0.66×C ACTR10 , C CA125 Represents the concentration value of CA125 in the subject's plasma, C ACTR10 Represents the concentration of ACTR10 in the subject's plasma vesicles; judging method: if C CA125 ≥35 (ie CA125 concentration ≥35U / ml) and 4.7CA125 <35 and -11<OCS1<10.3, the subject is judged to be stage I ovarian cancer.

[0087] According to whether the 100 model results are in the interval of 4.7 to 27.8, the r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention discloses application of combination of ACTR10 and CA125 in ovarian cancer detection and a kit, and relates to the field of medical diagnosis. The invention discloses preparation of a kit for ovarian cancer auxiliary diagnosis and / or ovarian cancer risk screening through combination of ACTR10 and CA125, the sensitivity and specificity of diagnosis are improved at the same time, and the effectiveness of ovarian cancer diagnosis is improved to a relatively high level.

Description

technical field [0001] The invention relates to the field of medical diagnosis, in particular to the application and kit of the combination of ACTR10 and CA125 in the detection of ovarian cancer. Background technique [0002] Ovarian cancer is currently the gynecological tumor with the highest mortality rate. The 5-year survival rate of advanced patients is about 20%, and when ovarian cancer is detected and treated at an early stage, the 5-year survival rate exceeds 90%. Early detection of ovarian cancer through screening is an important way to reduce the mortality of the disease. Tumor antigen 125 (abbreviated as CA125) and vaginal ultrasonography are currently the most commonly used methods for early screening of ovarian cancer. However, CA125 has no obvious role in the early diagnosis of ovarian cancer, and almost 50% of early ovarian cancer patients (stage I) have no significant increase in CA125. In addition, elevated CA125 is accompanied by false positive results, su...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886C12N15/11G16H50/20G16H50/30
CPCC12Q1/6886G16H50/20G16H50/30C12Q2600/158
Inventor 汪付兵王家亮邓伟黄梦飞
Owner 上海晟燃生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap